var data={"title":"Foscarnet: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Foscarnet: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/contributors\" class=\"contributor contributor_credentials\">Martin Rodriguez, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/contributors\" class=\"contributor contributor_credentials\">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 08, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> is principally used for the treatment of ganciclovir-resistant cytomegalovirus (CMV) infections in patients with the acquired immunodeficiency syndrome (AIDS) or in transplant recipients.</p><p>The mechanisms of action, pharmacokinetics, and adverse effects will be reviewed here. Treatment of the specific clinical syndromes can be found on the appropriate topic reviews.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> (trisodium phosphonoformate) is a pyrophosphate analog. It binds reversibly near the pyrophosphate-binding site of DNA polymerase (or reverse transcriptase) without requiring further modification [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. After binding, the drug blocks the cleavage of the pyrophosphate moiety from deoxynucleotide triphosphates, in turn halting DNA chain elongation. Foscarnet selectively inhibits viral polymerase; inhibition of mammalian DNA polymerase requires a 100-fold greater concentration of foscarnet than that required to block cytomegalovirus (CMV) replication [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">SPECTRUM OF ACTIVITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> inhibits the replication, at least in vitro, of multiple herpes family viruses, hepatitis B virus, and the human immunodeficiency virus (HIV) [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Clinically, foscarnet is employed almost exclusively to treat infections with cytomegalovirus (CMV) (particularly when <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> cannot be used) [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/2\" class=\"abstract_t\">2</a>] and acyclovir-resistant herpes simplex virus (HSV) and varicella zoster virus (VZV). Foscarnet has in vitro activity against human herpesvirus 6A and 6B, and has been used in a few cases [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/3\" class=\"abstract_t\">3</a>]. Foscarnet is <strong>not</strong> used as an antiretroviral agent to treat HIV.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">ANTIVIRAL RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Resistance testing can identify mutations that help predict the activity of <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/4-6\" class=\"abstract_t\">4-6</a>]. This can be used to guide antiviral therapy, especially in patients who have failed their initial regimen. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> resistance can result from mutations in the CMV UL54 gene, which encodes the DNA polymerase that is important for viral replication. Mutations in this gene reduce antiviral affinity. UL54 mutations can emerge during therapy with foscarnet, and can also emerge in the presence of prolonged <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> exposure, after the development of UL97 mutations (which confers resistance to ganciclovir but not to foscarnet).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> is not used as an anti-HIV agent, mutations in the HIV reverse transcriptase gene may result in HIV resistance to foscarnet [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/7\" class=\"abstract_t\">7</a>]. </p><p/><p><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> resistance is not seen in the presence of UL97 phosphotransferase mutations (seen in cytomegalovirus) or thymidine kinase mutations (seen in herpes simplex virus or varicella-zoster virus) since foscarnet does not require intracellular phosphorylation for antiviral activity. This is in contrast to the mechanism of resistance seen with <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> and <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>. (See <a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;</a> and <a href=\"topic.htm?path=ganciclovir-and-valganciclovir-an-overview\" class=\"medical medical_review\">&quot;Ganciclovir and valganciclovir: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">BASIC PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> has poor oral bioavailability and is therefore administered intravenously. Serum levels following a given dose can vary considerably, perhaps owing to differing equilibria resulting from foscarnet deposition in bone and cartilage [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Foscarnet is not significantly metabolized and is excreted solely by the kidneys, mainly via glomerular filtration and tubular secretion; bone and cartilage uptake accounts for roughly 20 percent of administered drug [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Peak concentrations with a regimen of 60 <span class=\"nowrap\">mg/kg</span> thrice daily or 90 <span class=\"nowrap\">mg/kg</span> twice daily range from about 400 to 700 <span class=\"nowrap\">micromol/L</span> [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Elimination follows a three-phase pattern, with half-lives of about 1 h, 3 to 7 h, and 88 h [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Clearance decreases with impaired renal function, and dose adjustment in patients with renal insufficiency is required. <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> is cleared by hemodialysis; concentrations in patients receiving 50 <span class=\"nowrap\">mg/kg</span> after dialysis were similar to those in patients with normal renal function receiving 90 <span class=\"nowrap\">mg/kg</span> twice daily [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. A small study found vitreous concentrations roughly comparable to concomitant plasma levels [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Specific toxicities are somewhat difficult to measure, given that <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> is used almost exclusively in patients with significant underlying illness who are often taking multiple medications. The most important adverse effects of foscarnet are decreased renal function, electrolyte abnormalities, and infusion-related nausea.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Renal insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>According to the drug's manufacturer in a 1993 tabulation, 27 percent of 188 AIDS patients receiving <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> in clinical trials experienced decreased renal function [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1,9\" class=\"abstract_t\">1,9</a>]. This impairment is usually reversible in persons with previously normal renal function [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> appears to be directly toxic to the renal tubular cells [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/10\" class=\"abstract_t\">10</a>]. Although tubular damage is probably the principal factor underlying foscarnet-induced renal dysfunction, the finding of crystals in the glomerular capillaries of three patients suggests that other mechanisms may contribute [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/11,12\" class=\"abstract_t\">11,12</a>]. In one case report, a patient developed crystal nephropathy and multiorgan failure after the use of foscarnet [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/13\" class=\"abstract_t\">13</a>].</p><p>The plasma creatinine concentration usually begins to rise after 6 to 15 days, the urinalysis is relatively bland, and biopsy tissue from a few patients has revealed acute tubular necrosis [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/14,15\" class=\"abstract_t\">14,15</a>]. The primary tubular injury can also explain the frequent polyuria and polydipsia via interference with the action of antidiuretic hormone&nbsp;[<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/16\" class=\"abstract_t\">16</a>]; in some cases, nephrogenic diabetes insipidus has occurred in the absence of an elevation in the plasma creatinine concentration [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/17\" class=\"abstract_t\">17</a>].</p><p>Renal toxicity appears to be reduced by concomitant saline (generally 0.5 to 1 L) administration. Administration of other nephrotoxic drugs such as amphotericin B along with <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> may increase the risk of renal insufficiency substantially [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/18,19\" class=\"abstract_t\">18,19</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Electrolyte abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypocalcemia is a well-established effect of <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a>, possibly via complex formation between the drug and free calcium [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/20\" class=\"abstract_t\">20</a>]. Hypomagnesemia is also commonly found and may contribute to the development of both hypocalcemia and hypokalemia [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1,20\" class=\"abstract_t\">1,20</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion\" class=\"medical medical_review\">&quot;Clinical manifestations of magnesium depletion&quot;</a>.) Other electrolyte disturbances that may occur include hypophosphatemia, hypercalcemia, and hyperphosphatemia [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Seizures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seizures have been associated with <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> in AIDS clinical trials, but it is unclear whether this effect reflects direct toxicity, drug-induced hypocalcemia, or underlying conditions [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Genital ulcerations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genital ulcerations have been linked to <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> therapy, and it is suspected that a topical toxic effect of the drug concentrated in urine is responsible [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. These lesions are reversible and potentially preventable with careful urinary hygiene.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anemia has been reported commonly in AIDS patients receiving <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a>, but, again, it is difficult to discern the degree of drug effect. Neutropenia, in contrast to the experience with <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>, is uncommon with foscarnet therapy [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Nausea</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infusion-related nausea afflicts about a quarter of persons receiving <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. This problem, combined with the requirement for concomitant hydration and need for electrolyte monitoring, make this drug more difficult to administer than <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">USE IN PREGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> has been assigned to Pregnancy Category C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table graphicRef50021 \">table 1</a>). Skeletal anomalies have been observed in rats, and there are no adequate studies in pregnant women. This drug should be used in pregnant patients only if the anticipated benefits clearly exceed the potential risk [<a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H1563820\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> is a pyrophosphate analog that inhibits viral replication by selectively binding to viral DNA polymerase. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In vitro, <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> inhibits the replication of multiple herpes family viruses, hepatitis B virus, and HIV. Clinically, foscarnet is used almost exclusively to treat patients with cytomegalovirus (CMV) infections, particularly when <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> cannot be used, and acyclovir-resistant herpes simplex virus (HSV) and varicella zoster virus (VZV). (See <a href=\"#H3\" class=\"local\">'Spectrum of activity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unlike <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> or <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>, <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> does not require intracellular phosphorylation for antiviral activity; thus, thymidine kinase mutations in HSV or VZV and UL97 phosphotransferase mutations in CMV do not confer drug resistance to foscarnet. (See <a href=\"#H4\" class=\"local\">'Antiviral resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> has poor oral bioavailability and is therefore administered intravenously. Clearance decreases with impaired renal function; dose adjustment of foscarnet is required. (See <a href=\"#H5\" class=\"local\">'Basic pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most important adverse effects of <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> are decreased renal function, electrolyte abnormalities, and infusion-related nausea. (See <a href=\"#H6\" class=\"local\">'Toxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The development of renal insufficiency on <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> is common among AIDS patients taking foscarnet, although renal impairment is usually reversible among patients with previously normal renal function. (See <a href=\"#H7\" class=\"local\">'Renal insufficiency'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypocalcemia is a well-established effect of <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a>, possibly via complex formation between the drug and free calcium. Hypomagnesemia is also common and may contribute to the development of both hypocalcemia and hypokalemia. (See <a href=\"#H8\" class=\"local\">'Electrolyte abnormalities'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> has been assigned to Pregnancy Category C. Skeletal anomalies have been observed in rats, and there are no adequate studies in pregnant women to assess toxicity or teratogenicity. (See <a href=\"#H13\" class=\"local\">'Use in pregnancy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/1\" class=\"nounderline abstract_t\">Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48:199.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/2\" class=\"nounderline abstract_t\">Tan BH. Cytomegalovirus Treatment. Curr Treat Options Infect Dis 2014; 6:256.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/3\" class=\"nounderline abstract_t\">Agut H, Bonnafous P, Gautheret-Dejean A. Update on infections with human herpesviruses 6A, 6B, and 7. Med Mal Infect 2017; 47:83.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/4\" class=\"nounderline abstract_t\">Le Page AK, Jager MM, Iwasenko JM, et al. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013; 56:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/5\" class=\"nounderline abstract_t\">Gregg K, Hakki M, Kaul DR. UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease. Transpl Infect Dis 2014; 16:320.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/6\" class=\"nounderline abstract_t\">Piret J, Boivin G. Antiviral drug resistance in herpesviruses other than cytomegalovirus. Rev Med Virol 2014; 24:186.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/7\" class=\"nounderline abstract_t\">Meyer PR, Matsuura SE, Zonarich D, et al. Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 2003; 77:6127.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/8\" class=\"nounderline abstract_t\">Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172:951.</a></li><li class=\"breakAll\">Astra Arcus. Foscarnet international prescribing information. March 1993.</li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/10\" class=\"nounderline abstract_t\">Trifillis AL, Cui X, Drusano GL. Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro. Antimicrob Agents Chemother 1993; 37:2496.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/11\" class=\"nounderline abstract_t\">Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998; 32:392.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/12\" class=\"nounderline abstract_t\">Goldfarb DS, Coe FL. Foscarnet crystal deposition and renal failure. Am J Kidney Dis 1998; 32:519.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/13\" class=\"nounderline abstract_t\">Philipponnet C, Michel PA, Daudon M, et al. Intravascular foscarnet crystal precipitation causing multiorgan failure. Am J Kidney Dis 2015; 65:152.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/14\" class=\"nounderline abstract_t\">Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1991; 1:1061.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/15\" class=\"nounderline abstract_t\">Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9:316.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/16\" class=\"nounderline abstract_t\">Navarro JF, Quereda C, Quereda C, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996; 27:431.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/17\" class=\"nounderline abstract_t\">Farese RV Jr, Schambelan M, Hollander H, et al. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med 1990; 112:955.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/18\" class=\"nounderline abstract_t\">Zaman MM, Burney S, Landman D, Quale JM. Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet. Clin Infect Dis 1996; 22:378.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/19\" class=\"nounderline abstract_t\">Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. Antiviral Res 2004; 61:73.</a></li><li><a href=\"https://www.uptodate.com/contents/foscarnet-an-overview/abstract/20\" class=\"nounderline abstract_t\">Guillaume MP, Karmali R, Bergmann P, Cogan E. Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS. Clin Infect Dis 1997; 25:932.</a></li><li class=\"breakAll\">Physicians' Desk Reference, 52nd ed, Medical Economics Company, Montvale, NJ 1998.</li></ol></div><div id=\"topicVersionRevision\">Topic 8288 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1563820\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">SPECTRUM OF ACTIVITY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">ANTIVIRAL RESISTANCE</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">BASIC PHARMACOKINETICS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">TOXICITY</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Renal insufficiency</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Electrolyte abnormalities</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Seizures</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Genital ulcerations</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Anemia</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Nausea</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">USE IN PREGNANCY</a></li><li><a href=\"#H1563820\" id=\"outline-link-H1563820\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8288|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/50021\" class=\"graphic graphic_table\">- Drug ratings in pregnancy (US Food and Drug Administration)</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">Acyclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion\" class=\"medical medical_review\">Clinical manifestations of magnesium depletion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ganciclovir-and-valganciclovir-an-overview\" class=\"medical medical_review\">Ganciclovir and valganciclovir: An overview</a></li></ul></div></div>","javascript":null}